Harvard Bioscience Stock Buy Hold or Sell Recommendation
| HBIO Stock | USD 3.69 0.03 0.81% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Harvard Bioscience is 'Sell'. Macroaxis provides Harvard Bioscience buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding HBIO positions. The advice algorithm takes into account all of Harvard Bioscience's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Harvard Bioscience's buy or sell advice are summarized below:
Real Value 4.33 | Target Price 6.42 | Hype Value 3.66 | Market Value 3.69 | Naive Value 3.34 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Harvard Bioscience given historical horizon and risk tolerance towards Harvard Bioscience. When Macroaxis issues a 'buy' or 'sell' recommendation for Harvard Bioscience, the advice is generated through an automated system that utilizes algorithms and statistical models.
Harvard |
Execute Harvard Bioscience Buy or Sell Advice
The Harvard recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Harvard Bioscience. Macroaxis does not own or have any residual interests in Harvard Bioscience or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Harvard Bioscience's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Harvard Bioscience Trading Alerts and Improvement Suggestions
| Harvard Bioscience generated a negative expected return over the last 90 days | |
| Harvard Bioscience has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 112.25 M. Net Loss for the year was (3.42 M) with profit before overhead, payroll, taxes, and interest of 62.29 M. | |
| Over 78.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Watch These 5 Technology Stocks for Q1 Earnings Beat or Miss |
Harvard Bioscience Returns Distribution Density
The distribution of Harvard Bioscience's historical returns is an attempt to chart the uncertainty of Harvard Bioscience's future price movements. The chart of the probability distribution of Harvard Bioscience daily returns describes the distribution of returns around its average expected value. We use Harvard Bioscience price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Harvard Bioscience returns is essential to provide solid investment advice for Harvard Bioscience.
| Mean Return | -0.15 | Value At Risk | -6.8 | Potential Upside | 6.43 | Standard Deviation | 3.73 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Harvard Bioscience historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Harvard Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Harvard Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Harvard Bioscience backward and forwards among themselves. Harvard Bioscience's institutional investor refers to the entity that pools money to purchase Harvard Bioscience's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Heartland Advisors Inc | 2023-12-31 | 866.5 K | Meros Investment Management, Lp | 2023-12-31 | 819.8 K | Geode Capital Management, Llc | 2023-12-31 | 804.6 K | Renaissance Technologies Corp | 2023-12-31 | 720.4 K | State Street Corporation | 2023-12-31 | 682.4 K | Portolan Capital Management, Llc | 2023-12-31 | 672.2 K | Northern Trust Corp | 2023-12-31 | 467.6 K | Greenwood Capital Associates, Llc | 2023-12-31 | 441.2 K | Acuitas Investments, Llc | 2023-12-31 | 326.5 K | B. Riley Asset Management, Llc | 2023-12-31 | 2.9 M | Punch & Associates Inv Mgmt Inc | 2023-12-31 | 2.9 M |
Harvard Bioscience Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation | 7.7M | 7.6M | 7.6M | 7.6M | 7.0M | 4.9M | |
| Other Non Cash Items | 2.3M | 1.9M | 280K | (3.6M) | 509K | 534.5K | |
| Capital Expenditures | 1.2M | 1.2M | 1.3M | 1.6M | 2.3M | 1.6M | |
| Net Income | (4.7M) | (7.8M) | (288K) | (9.5M) | (3.4M) | (3.6M) | |
| End Period Cash Flow | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
| Change To Inventory | 3.3M | 413K | (5.9M) | 252K | 1.5M | 1.6M | |
| Change In Cash | 162K | (18K) | (496K) | (3.3M) | (225K) | (213.8K) | |
| Free Cash Flow | 6.8M | 8.2M | (83K) | (438K) | 11.7M | 12.3M | |
| Change To Netincome | 5.0M | 5.2M | 4.2M | 4.4M | 5.1M | 3.4M | |
| Change Receivables | 468K | 3.1M | (4.3M) | 4.8M | 5.5M | 5.8M | |
| Net Borrowings | (7.4M) | (7.5M) | (52K) | (1.8M) | (2.1M) | (2.0M) | |
| Investments | (229K) | (1.4M) | (1.3M) | (1.6M) | (973K) | (1.0M) |
Harvard Bioscience Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Harvard Bioscience or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Harvard Bioscience's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Harvard stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.41 | |
β | Beta against NYSE Composite | 2.93 | |
σ | Overall volatility | 3.75 | |
Ir | Information ratio | -0.07 |
Harvard Bioscience Volatility Alert
Harvard Bioscience exhibits very low volatility with skewness of 0.1 and kurtosis of 0.44. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Harvard Bioscience's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Harvard Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Harvard Bioscience Fundamentals Vs Peers
Comparing Harvard Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Harvard Bioscience's direct or indirect competition across all of the common fundamentals between Harvard Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as Harvard Bioscience or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Harvard Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing Harvard Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Harvard Bioscience to competition |
| Fundamentals | Harvard Bioscience | Peer Average |
| Return On Equity | -0.047 | -0.31 |
| Return On Asset | 0.011 | -0.14 |
| Profit Margin | (0.03) % | (1.27) % |
| Operating Margin | 0.03 % | (5.51) % |
| Current Valuation | 199.07 M | 16.62 B |
| Shares Outstanding | 43.42 M | 571.82 M |
| Shares Owned By Insiders | 7.28 % | 10.09 % |
| Shares Owned By Institutions | 78.41 % | 39.21 % |
| Number Of Shares Shorted | 636.65 K | 4.71 M |
| Price To Earning | (25.00) X | 28.72 X |
| Price To Book | 2.53 X | 9.51 X |
| Price To Sales | 1.64 X | 11.42 X |
| Revenue | 112.25 M | 9.43 B |
| Gross Profit | 62.29 M | 27.38 B |
| EBITDA | 9.28 M | 3.9 B |
| Net Income | (3.42 M) | 570.98 M |
| Cash And Equivalents | 4.26 M | 2.7 B |
| Cash Per Share | 0.10 X | 5.01 X |
| Total Debt | 42.77 M | 5.32 B |
| Debt To Equity | 0.73 % | 48.70 % |
| Current Ratio | 2.42 X | 2.16 X |
| Book Value Per Share | 1.68 X | 1.93 K |
| Cash Flow From Operations | 14.03 M | 971.22 M |
| Short Ratio | 7.02 X | 4.00 X |
| Earnings Per Share | (0.08) X | 3.12 X |
| Price To Earnings To Growth | 2.89 X | 4.89 X |
| Target Price | 6.92 | |
| Number Of Employees | 391 | 18.84 K |
| Beta | 1.45 | -0.15 |
| Market Capitalization | 161.53 M | 19.03 B |
| Total Asset | 137.37 M | 29.47 B |
| Retained Earnings | (145.6 M) | 9.33 B |
| Working Capital | 22.5 M | 1.48 B |
Note: Acquisition by Cote Jennifer of 35800 shares of Harvard Bioscience subject to Rule 16b-3 [view details]
Harvard Bioscience Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Harvard . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Harvard Bioscience Buy or Sell Advice
When is the right time to buy or sell Harvard Bioscience? Buying financial instruments such as Harvard Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 83.4M | 72.2M | 73.1M | 82.7M | Total Assets | 162.3M | 145.4M | 137.4M | 124.6M |
Use Investing Ideas to Build Portfolios
In addition to having Harvard Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Harvard Bioscience Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Harvard Stock analysis
When running Harvard Bioscience's price analysis, check to measure Harvard Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harvard Bioscience is operating at the current time. Most of Harvard Bioscience's value examination focuses on studying past and present price action to predict the probability of Harvard Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harvard Bioscience's price. Additionally, you may evaluate how the addition of Harvard Bioscience to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Harvard Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.08) | Revenue Per Share 2.646 | Quarterly Revenue Growth (0.01) | Return On Assets 0.011 |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.